Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6185129 | Gynecologic Oncology | 2014 | 5 Pages |
Abstract
There has been an evolution in the acceptance of surrogate endpoints depending upon the clinical setting in ovarian cancer. While overall survival (OS) remains the most objective clinical trial endpoint, there is now realization that demanding OS as the primary endpoint has many obstacles. Ovarian cancer is a heterogeneous disease that is now divided by histologic subtypes. Future registration strategies will need to address disease heterogeneity. The exploration of currently acceptable clinical trial endpoints and alternative regulatory strategies will hopefully stimulate interest in novel drug development for patients with ovarian cancer.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Thomas J. Herzog, Ronald D. Alvarez, Angeles Secord, Barbara A. Goff, Robert S. Mannel, Bradley J. Monk, Robert L. Coleman,